Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
505.5 USD | +1.62% | +0.36% | -3.99% |
May. 30 | JPMorgan Adjusts Price Target on UnitedHealth to $559 From $546 | MT |
May. 30 | Baird Initiates UnitedHealth Group With Outperform Rating, $597 Price Target | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The firm trades with high earnings multiples: 27.34 times its 2024 earnings per share.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.99% | 458B | B- | ||
+14.60% | 126B | A- | ||
+12.56% | 97.01B | B- | ||
-21.17% | 43.89B | A- | ||
-5.48% | 37.96B | B- | ||
-26.95% | 2.65B | C+ | ||
-8.89% | 1.53B | B- | ||
+16.06% | 581M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- UNH Stock
- Ratings UnitedHealth Group Inc.